|Bid||161.09 x 1200|
|Ask||161.82 x 800|
|Day's range||160.33 - 170.74|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||264.20|
For instance, AMC Entertainment (NYSE: AMC) reported 2,252% revenue growth in its most recent quarter. Last year at this time, the COVID-19 lockdown was crushing a lot of stocks, with revenues dropping to near-zero for many companies. While some of these stocks are "turn around" stories, all of the stocks in this article have strong financials and are way safer than AMC.
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.